healthcare systems

Public Health officials seem not to realize the probable role of Covid-19 vaccines in hastening the development of stealth adapted coronaviruses. Indeed, they have still not accepted the existence of widespread human infections with stealth adapted monkey-derived viruses. These viruses were inadvertently introduced into humans from polio vaccines. This occurred as the consequence of using polio vaccines grown in the cultured kidney cells of cytomegalovirus infected monkeys.

A faulty assumption is that the current Covid-19 vaccines provide immunity that is comparable to that of natural infections. This is clearly not so. First, the vaccine is given by intramuscular injections, whereas natural infections occur via the respiratory mucosa. Intramuscular injections are not particularly effective in stimulating the development of mucosal immunoglobulin A (IgA) antibodies or resident cytotoxic T lymphocytes (CTL). The lowered level of vaccine induced mucosal immunity means that upon exposure to SARS-CoV-2 virus, a proportion of vaccinated individuals will likely acquire a persisting, subclinical infection that is restricted to the superficial respiratory mucosa. Public Health authorities allude to this possibility by insisting that those who are immunized will need to continue wearing masks. The persisting low-level infections will, however, provide the opportunity for the emergence of virus variants. Some of these will be more infectious, while others will be better able to evade vaccine evoked immunity and, therefore, become more widespread throughout the body.

The second major difference between the vaccine and natural infection is FDA’s allowance of the use of a single virus component in the vaccine, namely the spike protein. It is far easier for virus modification, or even deletion, of a single component than it is for concurrent changes to occur in the multiple antigens targeted by immunity to natural infections. Deletion of the spike protein is possible since coronaviruses have other means of entering into cells. The virus can then more easily undergo changes in the remaining genes that code for the relatively few virus components typically targeted by cellular immunity.

The persistence of subclinical infections due to the relative lack of mucosal immunity achieved by intramuscular injections and the systemic immune response being restricted to only the spike protein, can lead more rapidly than will natural infection, to the formation of stealth adapted coronaviruses. A corollary of this premise is that the English, South African, and Brazillian variants probably originated in individual participants of the Covid-19 vaccine trials conducted in each of the countries. With wider vaccine use, many more variants, including stealth adapted coronaviruses, are to be expected.

Stealth adaptation has another very concerning feature. It is the incorporation of additional genetic sequences that are probably required for the virus to regain infectivity. The added sequences can come from the cellular genome and from the genomes of other microbes. This has, for example, allowed polio vaccine derived stealth adapted viruses to bring monkey cellular sequences into humans.

The brain is particularly susceptible to symptomatic illnesses caused by stealth adapted viruses. These viruses can be cultured from patients with the chronic fatigue syndrome (CFS) and also from children with autism. The Long Covid syndrome has many clinical features in common with CFS. Until proven otherwise, the Long Covid syndrome should be considered as a viral illness with the potential of human to human transmission, including during pregnancy. It is critical to begin culturing blood samples from patients with the Long Covid syndrome and to sequence any resulting viruses.

Although the cellular immune system will normally not engage with stealth adapted viruses they can still be suppressed via the alternative cellular energy (ACE) pathway. This pathways has likely preceded photosynthesis in plants and the obtaining of energy by all life forms from the metabolism of food. In humans and animals, the brain is probably the major receiver of the life-force energy for the ACE pathway. The attracted energy is then transferred to the body’s fluids where it is expressed as an added kinetic activity. The energy is termed KELEA, an abbreviation for Kinetic Energy Limiting Electrostatic Attraction. KELEA can also be added to water, which is then termed KELEA excellerated water. Wearable pouches containing this water and inhaling nebulized mists from the water are being evaluated as simple means of enhancing the ACE pathway. These approaches can seemingly suppress both conventional and stealth adapted virus illnesses.

Most members of the biomedical research community have learned not to criticize vaccines. Indeed they sincerely believe in the safety and efficacy of vaccines. Sustaining this view has been a lack of disclosure by Government officials of actual long-term hazards of vaccines. An example for which I have some experience was the decision to use freshly harvested kidneys from rhesus monkeys to produce polio vaccines. Cells from the monkey kidneys were cultured and inoculated with the polio vaccine viruses.

An early finding was that many of the rhesus monkeys used to provide the kidneys were infected with Simian virus 40 (SV40). This particular problem was addressed in the early 1960s by switching from rhesus to African green monkeys. It was subsequently realized that both rhesus and African green monkeys were also commonly infected with their own type of cytomegalovirus. In a 1972 joint study by the US Food and Drug Administration (FDA) and the polio vaccine manufacturer, kidney cell cultures from 11 monkeys were set aside from polio vaccine production and tested for the presence of other viruses. All 11 cultures grew African green monkey simian cytomegalovirus (SCMV).

This information was withheld from the public, arguably because there had been no reports of cytomegalovirus infections occurring in polio vaccine recipients. Nor was this information brought to light when I informed the FDA that the virus, which I had repeatedly cultured from a woman with the chronic fatigue syndrome (CFS), had unequivocally originated from SCMV. What made this virus particularly noteworthy was the absence of any inflammation in the patient or in subsequently inoculated cats. The cats became acutely ill with evidence of severe brain damage. Interestingly, the animals showed clinical recovery in spite of the absence of immune stimulated inflammation.

By improving the virus culture methods, it became clear that the vast majority of CFS patients and many other patients with neuropsychiatric illnesses were virally infected. Yet the viruses, were not being effectively recognized by the cellular immune system. The infecting viruses were designated as being stealth adapted, with some clearly originating from SCMV. Children with autism were also shown to be uniformly stealth adapted virus infected. Public Health officials continued to remain disinterested, especially in response to the added suggestion that the AIDS epidemic possibly resulted from the testing of cytomegalovirus contaminated experimental polio vaccines in African chimpanzees.

Public Health authorities did, however, respond to learning about my testing of blood donors in 2002 for stealth adapted viruses. They needed to affirm their belief in the safety of the Nation’s blood supply by arguing that my reporting on these viruses had put the Nation’s health in Immediate Jeopardy. My further clinical testing for these viruses was legally prohibited. This demand gave ammunition to a disgruntled patient to begin pointless legal action and to the founder of a CFS patient support group to poison the internet with accusations of fraud and patient exploitation. In reality, I have never received personal income from the research.

The initial prototypical stealth adapted virus isolate had been largely sequenced, as had small regions on four other viruses. In the more fully characterized virus, there are deletions or mutations of the genes coding for the relatively few cytomegalovirus components that are normally targeted by the cellular immune system. There are also additional genetic sequences of cellular and bacterial origin. These “renegade” sequences may be necessary for the virus to regain its infectivity. Rhesus monkey cellular sequences have been incorporated into three of stealth adapted viruses for which there are limited sequence data. In one of these viruses some of the original monkey cellular sequences have been exchanged for human cellular sequences.

These findings are providing a new conceptual understanding of viruses. They can essentially become disguised as self or as a bacterial infection by incorporating either cellular or bacterial genetic sequences, respectively. Molecular methods applicable to the identification of conventional viruses are not as reliable as performing sensitive virus cultures. Of major significance is that the viruses can potentially act as carriers of disease-inducing cellular genes between individuals and even between animals and man.

Stealth adapted viruses have helped uncover a potent non-immunological anti-virus defense mechanism. The mode of virus suppression has been linked to an alternative cellular energy (ACE) pathway. This non-food source of energy is expressed as an added kinetic quality of the body’s fluids.

A greater willingness to understand, rather than to dismiss, the concept of stealth adaptation would have enabled Public Health to respond to the Covid-19 pandemic in a more effective manner. All of my efforts to communicate with the senior officials, including numerous e-mails with attachments and phone calls with staff members, have so far been unsuccessful. Broader discussions on this topic in social media may be helpful.